Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Non-Current Debt data on record, last reported at $92.3 million in Q3 2025.

  • For Q3 2025, Non-Current Debt fell 11.62% year-over-year to $92.3 million; the TTM value through Sep 2025 reached $92.3 million, down 11.62%, while the annual FY2024 figure was $102.5 million, 1.9% up from the prior year.
  • Non-Current Debt reached $92.3 million in Q3 2025 per BTAI's latest filing, down from $97.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $104.4 million in Q3 2024 and bottomed at $61.1 million in Q2 2022.
  • Average Non-Current Debt over 4 years is $95.6 million, with a median of $98.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: surged 58.57% in 2023, then fell 11.62% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $93.1 million in 2022, then increased by 8.11% to $100.6 million in 2023, then increased by 1.9% to $102.5 million in 2024, then dropped by 9.96% to $92.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $92.3 million in Q3 2025, $97.5 million in Q2 2025, and $99.9 million in Q1 2025.